Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance

Tost, Meritxell; González-Rodríguez, Alex; Aguayo, Raquel; Álvarez, Aida; Montalvo, Itziar; Barbero, Juan David; Gabernet, Rosa; Izquierdo, Eduard; Merodio, Igor; Monreal, José Antonio; Palao, Diego; Labad, Javier

doi:10.1016/j.pnpbp.2022.110619

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, risperidone blocks the D 1 receptor on the postsynaptic membrane of the midbrain cortical pathway, which might cause inattention and memory loss [ 45 ]. Olanzapine enhances cognitive function more effectively than risperidone and haloperidol [ 46 ]as well as reduces irritability, aggression, and insomnia [ 47 – 49 ]. Because it is safe and effective it is also used on children [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

Consensus on the pharmacological treatment of acute stress disorder in Chinese pilots: a Delphi study

Gao,

Wang,

Guo

et al. 2023

BMC Psychiatry

View full text Add to dashboard Cite

Background Appropriate medication is very important for pilots with acute stress disorder. Improper medication can not only affect the physical and mental health of the pilots but can also endanger flight safety. Hence, we aimed to quickly and effectively relieve symptoms and restore cognitive function by forming a consensus of Chinese experts on the pharmacological treatment of acute stress disorder in pilots using the Delphi method. Methods Relevant literature was searched to enumerate the current status of pharmacological treatment of acute stress disorder in pilots, followed by two rounds of expert consultation and discussion according to the listed status of the survey using the Delphi method. A descriptive statistical method was used to analyze the basic information, authority coefficients, concentration of opinions, and survey items of the experts to develop a consensus on the pharmacological treatment of acute stress disorder in pilots. Results A total of 16 experts in psychiatry, pharmacology, and aerospace medicine from different provinces and cities across China were invited for consultation. The recovery rate of the two rounds of consultation was 100%, and the expert authority coefficients were 0.897 and 0.906, respectively. Kendall’s coefficient of concordance of indicators at all levels was 0.564–0.594 (p < 0.01). Based on the number of votes received, alprazolam tablets (16), eszopiclone tablets (15), and lorazepam tablets (14) were recommended for the treatment of excitatory psychomotor symptoms of acute stress disorder; paroxetine tablets (15) and sertraline tablets (15) were available for psychomotor depressive symptoms; olanzapine tablets (15), olanzapine orally disintegrating tablets (14), and quetiapine fumarate tablets (14) were selected for psychotic symptoms. Conclusions This study formed a consensus on rapid and effective pharmacological treatment for different symptoms of acute stress disorder pilots, which provides a reference for clinical treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Consensus on the pharmacological treatment of acute stress disorder in Chinese pilots: a Delphi study

Gao,

Wang,

Guo

et al. 2023

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…However, the indirect costs of patients with schizophrenia can account for 50%-90% of the total cost, making it the main driver of the total cost (Kotzeva et al, 2023). A growing body of research has shown that long-acting antipsychotic injections can significantly improve the quality of life and prognosis of patients compared to oral medications (Gopal et al, 2020;Kim et al, 2021;Tost et al, 2023), suggesting that the actual benefits of PP1M and PP3M may be much greater than what has been observed. In addition, studies have demonstrated that PP1M and PP3M can significantly improve cognitive function (Suzuki et al, 2014;Takekita et al, 2016;Gopal et al, 2020;Tost et al, 2023), suggesting that patients with education and occupational needs may be better suited for treatment with PP1M and PP3M.…”

Section: Discussionmentioning

confidence: 99%

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China

Luo

Li³

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Long-acting injections (LAIs) of paliperidone palmitate have been shown to improve medication adherence and relieve psychotic symptoms. However, the specific cost-utility analysis of these LAIs in schizophrenia in China remains unclear.Methods: A multi-state Markov model was constructed to simulate the economic outcomes of patients with schizophrenia in China who received paliperidone palmitate 1-month formulation (PP1M), paliperidone palmitate 3-month formulation (PP3M), and paliperidone extended-release (ER). A cost-utility analysis was conducted, mostly derived from published literature and clinical databases. All costs and utilities were discounted at a rate of 5% per annum. The primary outcome measure was the incremental cost-effectiveness ratios (ICERs). A series of sensitivity analyses were also applied.Results: After 20 years, compared to ER, using PP1M resulted in an increased discounted cost from $36,252.59 to $43,207.28. This increased cost was associated with a gain in quality-adjusted life years (QALYs) from 8.60 to 9.45. As a result, the ICER for PP1M was estimated to be $8,247.46/QALY, which was lower than the willingness-to-pay (WTP) threshold of $12,756.55/QALY. When using PP3M instead of ER, the incremental cost was $768.81 and the incremental utility was 0.88 QALYs, projecting an ICER of $873.13/QALY, which was also lower than the WTP threshold of $12,756.55/QALY. The univariate sensitivity analysis showed that the costs of PP1M, PP3M, and ER had the greatest impact on ICERs. The probability sensitivity analysis (PSA) revealed that when the WTP thresholds were $12,756.55/QALY, the probability of PP1M and PP3M being cost-effective was 59.2% and 66.0%, respectively.Conclusion: From the Chinese healthcare system perspective, PP3M and PP1M are both more cost-effective compared to ER, and PP3M has notable cost-utility advantages over PP1M.

show abstract

Sex differences in changes in prolactin levels and sexual function after switching from risperidone to paliperidone palmitate in schizophrenia

Tost,

Barbero,

Montalvo

et al. 2024

The European Journal of Psychiatry

View full text Add to dashboard Cite

Switching from risperidone to paliperidone palmitate in schizophrenia: Changes in social functioning and cognitive performance

Cited by 4 publications

References 33 publications

Consensus on the pharmacological treatment of acute stress disorder in Chinese pilots: a Delphi study

Consensus on the pharmacological treatment of acute stress disorder in Chinese pilots: a Delphi study

Cost-utility analysis of using paliperidone palmitate in schizophrenia in China

Sex differences in changes in prolactin levels and sexual function after switching from risperidone to paliperidone palmitate in schizophrenia

Contact Info

Product

Resources

About